Medivation Announces Presentation of Phase I Talazoparib Combination Data in Several Advanced Cancers
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Medivation (MDVN) Preclinical Excitement Seems To Be Bearing Fruit - Stifel
April 18, 2016 9:59 AM EDTStifel analyst, Thomas Shrader, thinks that preclinical excitement for Medivation's (NASDAQ: MDVN) talazoparib is bearing fruit. Much of Medivations excitement in Talazoparib is based on the drugs ability to trap the PARP enzyme on the DNA and act like a Topo II inhibitor in addition to inhibiting PARP enzymatic activity. Topo II inhibitors from the anthracycline family are the most broadly active drugs... More
